Galectin Therapeutics reported $-11.29M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Gilead Sciences USD 3.85B 1.17B Jun/2026
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD -707.47M 1.41B Sep/2026
Merck USD 7.33B 6.49B Sep/2026